Targeting of CD122 enhances antitumor immunity by altering the tumor immune environment

Oncotarget

Volumn 8, Issue 65, 2017, Pages 109151-109160

  Villarreal, Daniel O ^a   Allegrezza, Michael J ^a   Smith, Melissa A ^a   Chin, Diana ^a   Luistro, Leopoldo L ^a   Snyder, Linda A ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

CD122; CD8 T cells; GITR; Immunotherapy; Vaccines

Indexed keywords

INTERLEUKIN 2 RECEPTOR BETA;

ANIMAL CELL; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; FEMALE; GRANULOCYTIC MYELOID DERIVED SUPPRESSOR CELL; IN VITRO STUDY; IN VIVO STUDY; LONG TERM SURVIVAL; MOUSE; MYELOID-DERIVED SUPPRESSOR CELL; NONHUMAN; PROTEIN FUNCTION; PROTEIN TARGETING; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

EID: 85037688370     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.22642     Document Type: Article

References (22)

1. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007; 25:267-96
2. Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, Kuniyasu Y, Nomura T, Toda M, Takahashi T. Immunologic tolerance maintained by CD25+Cd4+ regulaotry T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev. 2001; 182:18-32
3. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: Mechanisms of differentiation and function. Annu Rev immunol. 2012; 30:531-564
4. Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends immunol. 2016; 37:208-20
5. Li S, Xie Q, Zeng Y, Zou C, Liu X, Wu S, Deng H, Xu Y, Li XC, Dai Z. A naturally occurring CD8+CD122+ T-cell subset as a memory-like Treg family. Cell Mol Immunol. 2014; 11:326-31
6. Endharti AT, Rifa'I M, Shi Z, Fukuoka Y, Nakahara Y, Kawamoto Y, Takeda K, Isobe K, Suzuki H. Cutting edge: CD8+CD122+ regulatory T cells produce IL-10 to suppress IFN-y production and proliferation of CD8+ T cells. J Immunol. 2005; 175:7093-7097
7. Wang LX, Li Y, Yang G, Pang PY, Haley D, Walker EB, Urba WJ, Hu HM. CD122+CD8+ Treg suppress vaccineinduced antitumor immune responses in lymphodepleted mice. Eur J Immunol. 2010; 40:1375-85
8. Rifa'i M, Kawamoto Y, Nakashima I, Suzuki H. Essential roles of CD8+CD122+ regulatory T cells in the maintenance of T cell homeostasis. J Exp Med. 2004; 200:1123-1134
9. Arndt B, Witkowski L, Ellwart J, Seissler J. CD8+CD122+PD-1-effector cells promote the development of diabetes in NOD mice. J Leukoc Biol. 2015; 97:111-20
10. Yu P, Bamford RN, Waldmann TA. IL-15-dependent CD8+CD122+ T cells ameliorate experimental autoimmune encephaloymyelitis by modulating IL-17 production by CD4+ T cells. Eur J Immunol. 2014; 44:3330-3341
11. Lee Yh, Ishida Y, Rifa'I M, Shi Z, Isobe K, Suzuki H. Essential role of CD8+CD122+ regulatory T cells in the recovery from experimental autoimmune encephalomyelitis. J Immunol. 2008; 180:825-32
12. Mairhofer DG, Ortner D, Tripp CH, Schaffenrath S, Fleming V, Heger L, Komenda K, Reider D, Dudziak D, Chen S, Becker JC, Flacher V. Impaired gp100-specific CD8 T-cell responses in the presence of myeloid-derived suppressor cells in a spontaneous mouse melanoma model. J Invest Dermatol. 2015; 135:2785-93
13. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol. 2008; 181:5791-802
14. Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, McDermott D, Quiceno D, Youmans A, O'Neill A, Mier J, Ochoa AC. Arginaseproducing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 2005; 65:3044-8
15. Fujiwara S, Nagai H, Shimoura N, Oniki S, Yoshimoto T, Nishigori C. Intratumoral CD4 T lymphodepletion sensitizes poorly immunogenic melanomas to immunotherapy with an OX40 agonist. J Invest Dermatol. 2014; 134:1884-92
16. Kline J, Zhang L, Battaglia L, Cohen KS, Gajewski TF. Cellular and molecular requirments for rejection of b16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation. J Immunol. 2012; 188:2630-42
17. Cohen AD, Diab A, Perales MA, Wolchok JD, Rizzuto G, Merghoub T, Huggins D, Liu C, Turk MJ, Restifo NP, Sakaguchi S, Houghton AN. Agonist anti-GITR antibody enhances vaccine-induced CD8 T cell responses and tumor immunity. Cancer Res. 2006; 66:9
18. Couper KN, Lanthier PA, Perona-Wright G, Kummer LW, Chen W, Smiley ST, Mohrs M, Johnson LL. Anti-CD25 antibody-mediated depletion of effector T cell populations enhances susceptibility of mice to acute but not chronic toxoplasma gondii infection. J Immunol. 2009; 182:3985-94
19. Schaer DA, Murphy JT, Wolchok JD. Modulation of GITR for cancer immunotherapy. Curr Opin Immunol. 2012; 24:217-224
20. Villarreal DO, Chin D, Smith MA, Luistro LL, Snyder LA. Combination GITR targeting/PD_1 blockade with vaccination drives robust antigen-specific antitumor immunity. Oncotarget. 2017; 8:39117-39130. http://doi.org/10.18632/oncotarget.16605
21. Furse RK, Malek TR. Selection of internalization-deficient cells by interleukin-2-pseudomonas exotoxin chimeric protein: the cytoplasmic domain of the interleukin-2 receptor beta chain does not contribute to internalization of interleukin-2. Eur J Immunol. 1993; 23:3181-3188
22. Ronchetti S, Ricci E, Petrillo MG, Cari L, Migliorati G, Nocentini G, Riccardi C. Glucocorticoid-induced tumour necrosis factor receptor-related protein: a key marker of functional regulatory T cells. J Immunol Research. 2015; 2015:171520